IMD is focused on advancing Intrexon’s oncology and immunology platforms to bring the next generation of cellular-based solutions that overcome the limitations of current therapies and address the most challenging malignancies. In cancer, the treatment of patients has relied heavily on three pillars of disease management, namely surgery, chemotherapy and radiation. Immuno-Oncology is a rapidly evolving fourth pillar, which seeks to leverage the patient’s own immune system to eradicate cancer. Therapies based on the direct adaptation of immune responses have the potential to revolutionize cancer treatment and bring substantial value to patients and their families. While significant benefits for patients have been observed from early clinical trials of T-cell and NK based immunotherapies, toxicities have also been observed.
A core focus of IMD’s Immuno-Oncology team is to redirect T or NK cells for example using chimeric antigen receptors (CARs) or T cell receptors (TCRs) to eliminate patient’s tumor cells. Leveraging a number of Intrexon technologies including the RheoSwitch® platform, we can regulate therapeutic gene expression in these therapy motiffs. The development of controllable immunotherapies has the potential to mobilize as well as regulate potent anti-cancer immune responses, providing an unprecedented level of safety and precise targeting ability above and beyond current alternatives. With its suite of DNA engineering technologies and expertise in synthetic immunology, Intrexon is well positioned to develop new approaches to increase safety as well as efficacy for patients and move the field of cellular immunotherapy forward.